Aims To systematically investigate the effect of interventions to overcome therapeutic inertia
on glycaemic control in individuals with type 2 diabetes. Materials and Methods We …

Aims Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely
manner according to evidence‐based clinical guidelines, is a key reason for uncontrolled …

The current epidemic of type 2 diabetes (T2D) represents a significant global and national
health concern. Globally, the prevalence of diabetes has doubled between 1980 and 2014 …

Early glycaemic control leads to better outcomes, including a reduction in long-term
macrovascular and microvascular complications. Despite good-quality evidence, glycaemic …

Many people with diabetes do not achieve individualized treatment targets. Therapeutic
inertia, the underuse of effective therapies in preventing serious clinical end points, is a …

Diabetes mellitus is a chronic disease characterized by high social, economic and health
burden, mostly due to the high incidence and morbidity of diabetes complications …

Aims Clinical inertia, the tendency to maintain current treatment strategies despite results
demanding escalation, is thought to substantially contribute to the disconnect between …

Research has shown that getting to glycemic targets early on leads to better outcomes in
people with type 2 diabetes; yet, there has been no improvement in the attainment of A1C …

Despite clinical practice guidelines that recommend frequent monitoring of HbA1c (every 3
months) and aggressive escalation of antihyperglycemic therapies until glycemic targets are …

Objective: To assess clinical inertia, defined as failure to intensify antidiabetic treatment of
patients who have not achieved the HbA1c therapeutic goal (≤ 7%). Research design and …